SCHEMBL4474062

SCHEMBL4474062

Nc1nc(-c2c[nH]c3ncccc23)cs1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 7/20 0.63
CDK9 P50750 4/20 0.63
CDK5 Q00535 4/20 0.63
CDK2 P24941 2/20 0.63
CCNT1 O60563 1/20 0.63
CCNA2 P20248 1/20 0.63
CCNA1 P78396 1/20 0.63
CDK5R1 Q15078 1/20 0.63
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
RAB9A P51151 2/20 0.62
KDM4E B2RXH2 1/20 0.62
ALDH1A1 P00352 1/20 0.62
MAPT P10636 1/20 0.62
THRB P10828 1/20 0.62
ALOX15 P16050 1/20 0.62
PPARG P37231 1/20 0.62
NCOA2 Q15596 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
HSD17B10 Q99714 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23163147 0.87 CDK9 (0.57) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL4789520 0.83 PDPK1 (0.58) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL12281263 0.82 CDK9 (0.53) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL23163770 0.82 ROCK1 (0.54) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL17243071 0.81 RAB9A (0.61) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL12321654 0.80 CDK9 (0.51) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL1842617 0.79 PDPK1 (0.56) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL23163137 0.79 CDK1 (0.57) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL29364420 0.78 PRKCI (0.63) PDPK1CDK9CDK5CDK2CCNT1
SCHEMBL25787852 0.78 PRKCI (0.63) PDPK1CDK9CDK5CDK2CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514448-B2 Azaindoles useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-07 US disclosed
US-7514448-B2 Azaindoles useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-07 US disclosed
US-7514448-B2 Azaindoles useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-07 US disclosed
CN-101014597-A Azaindoles useful as inhibitors of rock and other protein kinases VERTEX PHARMA (US) 2007-08-08 CN disclosed
EP-1756108-A2 AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2007-02-28 EP disclosed
US-20060003968-A1 Azaindoles useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2006-01-05 US disclosed
WO-2005103050-A2 AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060003968-A1 Azaindoles useful as inhibitors of rock and other protein kinases ROCK2, ROCK1, TNK2 PDPK1 196/4885CDK9 269/4885CDK5 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.